On October 28, 2025, Genprex, Inc. announced positive preclinical results for its lead drug candidate, Reqorsa®, at the AACR-NCI-EROTC International Conference, showing improved outcomes for ALK+ non-small cell lung cancer. These results suggest potential for future clinical trials in patients, highlighting the drug's effectiveness alone and in combination with alectinib.